Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology presented a 5-year analysis of its Phase III ExteNET trial results in extended adjuvant HER2+ breast cancer at ESMO's 2017 Congress

Puma Biotechnology, Inc.